Body mass index influences the response to infliximab in ankylosing spondylitis

@inproceedings{Ottaviani2012BodyMI,
  title={Body mass index influences the response to infliximab in ankylosing spondylitis},
  author={S{\'e}bastien Ottaviani and Yannick Allanore and Florence Tubach and Marine Forien and Ana{\"i}s Gardette and Blandine Pasquet and Elisabeth Palazzo and Marine Meunier and Gilles Hayem and Chantal Job-Deslandre and Andr{\'e} Kahan and Olivier Meyer and Philippe Dieud{\'e}},
  booktitle={Arthritis research & therapy},
  year={2012}
}
INTRODUCTION The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetic consequences. The aim of this study was to determine whether body mass index (BMI) affects response to infliximab (IFX) in ankylosing spondylitis (AS) patients. METHODS In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously). After 6 months of treatment, changes from baseline in BASDAI, Visual… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Weight and response to biologics in RA and spondylarthritides: obesity reduces the rate of remission-response: The GISEA Registry [Abstract

  • G Ferraccioli, F Trotta, +10 authors G Lapadula
  • Arthritis Rheum
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…